Vaccines - Indonesia

Indonesia

The Vaccines market in Indonesia is anticipated to achieve a revenue of US$0.34bn in 2024.
It is expected to exhibit a steady annual growth rate (CAGR 2024-2028) of -3.90%, leading to a market volume of US$0.29bn by 2028.
In terms of global comparison, United States is projected to generate the highest revenue of US$25,690.00m in 2024.
Indonesia's growing population and increasing awareness of preventive healthcare are driving the demand for vaccines in the country.

Key regions: South Korea, India, China, Australia, Italy

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Indonesia has been increasing steadily in recent years.

Customer preferences: Indonesian customers are becoming more health-conscious and aware of the importance of vaccines. This is partly due to the government's efforts to promote vaccination campaigns, especially for children. Additionally, the COVID-19 pandemic has further highlighted the importance of vaccines and has led to an increase in demand for them.

Trends in the market: One of the major trends in the vaccines market in Indonesia is the increasing demand for new and innovative vaccines. This is driven by the government's efforts to expand the national immunization program and the growing awareness among consumers about the benefits of vaccines. Furthermore, the rise of medical tourism in Indonesia has also contributed to the growth of the vaccines market, as more people are traveling to the country for medical treatments, including vaccinations.

Local special circumstances: Indonesia is the fourth most populous country in the world, with a large and diverse population spread across many islands. This presents unique challenges for the distribution and administration of vaccines, especially in remote and rural areas. To address this, the government has launched various initiatives to improve access to vaccines, including mobile vaccination units and community health centers.

Underlying macroeconomic factors: Indonesia's economy has been growing steadily in recent years, with a growing middle class and increasing disposable income. This has led to an increase in demand for healthcare services, including vaccines. Additionally, the government has been investing heavily in healthcare infrastructure and facilities, which has helped to boost the vaccines market. However, there are also challenges in the market, including regulatory hurdles and the high cost of developing and manufacturing vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.